Continuous Glucose Monitoring Devices Market Revenue & Forecast Analysis, 2026-2035
The continuous glucose monitoring devices market was valued at USD 13.5 billion in 2025, and is expected to grow at a CAGR of 15.1% from USD 15.4 billion in 2026 to USD 54.9 billion in 2035. The strong market expansion is mainly fueled by the escalating global incidence of diabetes, heightened awareness regarding the significance of continuous glucose monitoring, and the increasing use of advanced diabetes management technologies. Additionally, technological innovations like factory-tuned sensors, wearable and minimally invasive CGM devices, smartphone integration, cloud-based data sharing, and AI-driven glucose analysis are improving user convenience and clinical results.
Market Overview
The Centers for Disease Control and Prevention reported that around 38.4 million individuals in the United States had diabetes in 2021, accounting for approximately 11.6% of the population, which continues to fuel the demand for continuous glucose monitoring (CGM) devices.
The Continuous Glucose Monitoring (CGM) devices market has seen significant expansion over time, fueled by the rising global incidence of diabetes, greater acceptance of real-time glucose tracking technologies, and heightened awareness of efficient diabetes management. The market has gained even more from technological progress like factory-calibrated sensors, wearable continuous glucose monitoring devices, smartphone connectivity, and the integration with insulin pumps and automated insulin delivery systems. For instance, in 2024, Dexcom, Inc. broadened the accessibility of its advanced CGM systems, promoting better glycemic control and boosting uptake among Type 1 and Type 2 diabetes patients globally.
The Continuous Glucose Monitoring (CGM) Devices market is projected to experience significant growth throughout the forecast period due to rising demand for tailored diabetes management, broader reimbursement options, and ongoing advancements in sensor precision and digital health innovations. The increasing incorporation of artificial intelligence, cloud-based remote patient monitoring, and compatible diabetes management systems is anticipated to boost market growth even more. For instance, by 2035, it is anticipated that the use of sophisticated CGM devices linked with automated insulin delivery systems will rise considerably in global healthcare environments, fueled by the demand for better glycemic management, increased patient ease, and minimised diabetes-related complications.
Continuous Glucose Monitoring Devices Market Overview
Base Year Market Size (2025): USD 13.5 Billion
CAGR: 15.1%
Forecast Year Market Size (2035): USD 54.9 Billion
Leading Region: North America
Emerging Countries: China, India, Brazil, South Korea, United Arab Emirates (UAE)
Major Players:
Abbott Laboratories
Dexcom, Inc.
F. Hoffmann-La Roche Ltd
Medtronic plc
Senseonics Holdings, Inc.
Continuous Glucose Monitoring Devices Market Trends
The Continuous Glucose Monitoring (CGM) devices market is rapidly expanding, fueled by the rising incidence of diabetes, ongoing technological improvements, and the rising trend toward personalised and digital management of diabetes.
A major trend is the growing use of wearable and factory-calibrated CGM systems, which allow real-time glucose monitoring with greater precision and added convenience for patients.
The market is experiencing increasing integration of CGM devices with insulin pumps and automated insulin delivery (AID) systems, enhancing diabetes management and minimising the risk of hypoglycemic and hyperglycemic occurrences.
The integration of artificial intelligence (AI), cloud data systems, and smartphone connectivity is facilitating remote patient monitoring, predictive glucose analysis, and enhanced clinical decision-making.
Additionally, key manufacturers are concentrating on compact sensors, prolonged sensor usage, non-invasive tracking technologies, and enhanced interoperability with digital health systems to improve user experience and bolster their market presence.
Overall, these trends are speeding up the shift to connected, AI-driven, and patient-focused diabetes management, fostering the ongoing expansion of the Continuous Glucose Monitoring (CGM) Devices Market.
Continuous Glucose Monitoring Devices Market Analysis
By Product Type
Sensors dominate the Continuous Glucose Monitoring (CGM) Devices Market due to their essential role in providing accurate, real-time glucose measurements and the need for regular sensor replacement
Based on the product type, the Continuous Glucose Monitoring (CGM) Devices Market is categorised into sensors, devices/readers, applicators, and transmitters. The sensors segment leads the market with the highest market share of 61.31% in 2025.
By Connectivity Outlook
Bluetooth dominates the Continuous Glucose Monitoring (CGM) Devices market due to its seamless smartphone connectivity and real-time glucose data transmission capability.
Based on the connectivity outlook, the Continuous Glucose Monitoring (CGM) Devices market is categorized into Bluetooth, 4G/Cellular, and Near Field Communication (NFC). The Bluetooth segment leads the market with the highest share in 2025.
By Indication
Type 1 Diabetes dominates the Continuous Glucose Monitoring (CGM) Devices Market due to lifelong insulin dependence and the critical need for continuous, real-time glucose monitoring.
Based on the indication, the Continuous Glucose Monitoring (CGM) Devices market is categorized into type 1 diabetes, type 2 diabetes, gestational diabetes, and others. The type 1 diabetes segment leads the market with the highest share in 2025.
By End-use
Home Care Settings dominate the Continuous Glucose Monitoring (CGM) Devices Market due to the rising preference for remote, patient-centric diabetes management and wearable monitoring devices.
Based on the end-use, the Continuous Glucose Monitoring (CGM) Devices market is categorized into home care settings, hospitals & clinics, and ambulatory care centers. The home care settings segment leads the market with the highest share in 2025.
Regional Analysis
North America dominates the Continuous Glucose Monitoring (CGM) Devices Market due to high diabetes prevalence, strong healthcare infrastructure, and early adoption of advanced wearable technologies
North America accounted for the largest share of the Continuous Glucose Monitoring (CGM) Devices market in 2025.
Europe is emerging as a key CGM market, supported by growing diabetes awareness and increasing adoption of advanced glucose monitoring technologies
Europe is expected to witness strong growth during the forecast period, driven by rising diabetes cases, expanding access to advanced CGM devices, increasing healthcare expenditure, supportive government initiatives for chronic disease management, and growing adoption of digital and connected diabetes care solutions across major European countries.
Key Companies Profiled
The Continuous Glucose Monitoring (CGM) Devices market is very competitive and somewhat consolidated, with several top global medical device firms in control due to robust product lines, ongoing advancements in wearable sensor technology, and the growth of digital diabetes management systems. The market features strong competition in sensor precision, integration of devices with insulin delivery systems, and solutions for real-time data connectivity.
Prominent companies like Abbott Laboratories, Dexcom, Inc., Medtronic plc, and F. Hoffmann-La Roche Ltd collectively hold a substantial portion of the global CGM market, fueled by their well-established CGM systems, robust clinical acceptance, and ongoing R&D investments in advanced glucose monitoring technologies.
The competitive landscape is becoming more intense due to rising demand for minimally invasive, long-lasting sensors, AI-driven glucose analytics, and integrated smartphone monitoring solutions. Collaborative alliances with healthcare providers, growth into developing markets, and integration with automated insulin delivery systems are anticipated to enhance the standing of top firms and influence the future market landscape.
Continuous Glucose Monitoring Devices Market Companies:
Abbott Laboratories
AgaMatrix
ARKRAY Inc.
Ascensia Diabetes Care
B. Braun Melsungen AG
DarioHealth Corp.
Dexcom, Inc.
F. Hoffmann-La Roche Ltd
Insulet Corporation
Medisana AG
Medtronic plc
Senseonics Holdings, Inc.
Sinocare Inc.
Tandem Diabetes Care
Trividia Health
Ypsomed AG
Market Segmentation
This study provides revenue growth and emerging trends across global, regional, and country levels from 2021 to 2035, segmenting the continuous glucose monitoring devices market by-
Product Type (Revenue in USD Million, 2021 - 2035)
Sensors
Device/Readers
Applicators
Transmitters
Connectivity Outlook (Revenue in USD Million, 2021 - 2035)
Bluetooth
4G/Cellular
Near Field Communication (NFC)
Indication (Revenue in USD Million, 2021 – 2035)
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Others
End-use (Revenue in USD Million, 2021 – 2035)
Home Care Settings
Hospitals & Clinics
Ambulatory Care Centers
Regional (Revenue in USD Million, 2021 - 2035)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Switzerland
Netherlands
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Indonesia
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Content
1. Methodology and Scope
1.1. Scope of the Study
1.1.1. Market Segmentation
1.1.2. Market Definition
1.1.3. Inclusions and Exclusions of the Study
1.2. Research Design
1.2.1. Base Year, Historical Data, and Forecast Period
1.2.2. Data Collection Methods
1.2.2.1. Secondary Sources
1.2.2.2. Primary Sources
1.2.3. Research Methodology
1.2.3.1. Base Year Calculation/ Parent Market Analysis, Company/ Brand Share Analysis, 2025 (Top-down Approach)
1.2.3.2. Volume-Price Approach (Bottom-up Approach)
1.2.3.3. Data Triangulation
1.2.4. Forecasting Model
1.3. Research Assumptions
1.4. Validation and Data Quality Control
1.5. List of Primary Sources
1.6. List of Secondary Sources
2. Executive Summary
2.1. Market Overview
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
3. Industry Outlook
3.1. Industry Ecosystem Analysis
3.2. Parent/ Ancillary Market Analysis
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints/ Challenges
3.3.3. Opportunities
3.4. Consumer Behaviour Analysis
3.5. Value Chain Analysis
3.6. Technology Roadmap
3.7. Porters Analysis
3.8. PESTLE Analysis
4. Market Estimates and Forecasts, By Product Type, 2021 - 2035 (Market Size in USD Mn)
4.1. Sensors
4.2. Device/Readers
4.3. Applicators
4.4. Transmitters
5. Market Estimates and Forecasts, By Connectivity Outlook, 2021 – 2035 (USD Mn)
5.1. Bluetooth
5.2. 4G/Cellular
5.3. Near Field Communication (NFC)
6. Market Estimates and Forecasts, By Indication, 2021 – 2035 (USD Mn)
6.1. Type 1 Diabetes
6.2. Type 2 Diabetes
6.3. Gestational Diabetes
6.4. Others
7. Market Estimates and Forecasts, By End-use, 2021 – 2035 (USD Mn)
7.1. Home Care Settings
7.2. Hospitals & Clinics
7.3. Ambulatory Care Centers
8. Market Estimates and Forecasts, By Region, 2021 - 2035 (USD Mn)
8.1. North America
8.1.1. U.S.
8.1.1.1. U.S. Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.1.1.2. Market Dynamics
8.1.1.3. Competitive Landscape
8.1.1.4. Regulatory Framework
8.1.1.5. Reimbursement Scenario
8.1.2. Canada
8.1.2.1. Canada Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.1.2.2. Market Dynamics
8.1.2.3. Competitive Landscape
8.1.2.4. Regulatory Framework
8.1.2.5. Reimbursement Scenario
8.2. Europe
8.2.1. Germany
8.2.1.1. Germany Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.1.2. Market Dynamics
8.2.1.3. Competitive Landscape
8.2.1.4. Regulatory Framework
8.2.1.5. Reimbursement Scenario
8.2.2.
8.2.3. U.K.
8.2.3.1. UK Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.3.2. Market Dynamics
8.2.3.3. Competitive Landscape
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.4. France
8.2.4.1. France Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.4.2. Market Dynamics
8.2.4.3. Competitive Landscape
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.5. Italy
8.2.5.1. Italy Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.5.2. Market Dynamics
8.2.5.3. Competitive Landscape
8.2.5.4. Regulatory Framework
8.2.5.5. Reimbursement Scenario
8.2.6. Spain
8.2.6.1. Spain Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.6.2. Market Dynamics
8.2.6.3. Competitive Landscape
8.2.6.4. Regulatory Framework
8.2.6.5. Reimbursement Scenario
8.2.7. Sweden
8.2.7.1. Sweden Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.7.2. Market Dynamics
8.2.7.3. Competitive Landscape
8.2.7.4. Regulatory Framework
8.2.7.5. Reimbursement Scenario
8.2.8. Norway
8.2.8.1. Norway Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.8.2. Market Dynamics
8.2.8.3. Competitive Landscape
8.2.8.4. Regulatory Framework
8.2.8.5. Reimbursement Scenario
8.2.9. Denmark
8.2.9.1. Denmark Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.9.2. Market Dynamics
8.2.9.3. Competitive Landscape
8.2.9.4. Regulatory Framework
8.2.9.5. Reimbursement Scenario
8.2.10. Switzerland
8.2.10.1. Switzerland Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.10.2. Market Dynamics
8.2.10.3. Competitive Landscape
8.2.10.4. Regulatory Framework
8.2.10.5. Reimbursement Scenario
8.2.11. Netherlands
8.2.11.1. Netherlands Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.11.2. Market Dynamics
8.2.11.3. Competitive Landscape
8.2.11.4. Regulatory Framework
8.2.11.5. Reimbursement Scenario
8.2.12. Rest of Europe
8.2.12.1. Rest of Europe Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.2.12.2. Market Dynamics
8.2.12.3. Competitive Landscape
8.2.12.4. Regulatory Framework
8.2.12.5. Reimbursement Scenario
8.3. Asia Pacific
8.3.1. China
8.3.1.1. China Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.1.2. Market Dynamics
8.3.1.3. Competitive Landscape
8.3.1.4. Regulatory Framework
8.3.1.5. Reimbursement Scenario
8.3.2. Japan
8.3.2.1. Japan Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.2.2. Market Dynamics
8.3.2.3. Competitive Landscape
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.3. India
8.3.3.1. India Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.3.2. Market Dynamics
8.3.3.3. Competitive Landscape
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.4. Australia
8.3.4.1. Australia Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.4.2. Market Dynamics
8.3.4.3. Competitive Landscape
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.5. South Korea
8.3.5.1. South Korea Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.5.2. Market Dynamics
8.3.5.3. Competitive Landscape
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.6. Thailand
8.3.6.1. Thailand Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.6.2. Market Dynamics
8.3.6.3. Competitive Landscape
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.7. Indonesia
8.3.7.1. Indonesia Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.7.2. Market Dynamics
8.3.7.3. Competitive Landscape
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.8. Rest of Asia Pacific
8.3.8.1. Rest of Asia Pacific Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.3.8.2. Market Dynamics
8.3.8.3. Competitive Landscape
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.4. Latin America
8.4.1. Brazil
8.4.1.1. Brazil Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.4.1.2. Market Dynamics
8.4.1.3. Competitive Landscape
8.4.1.4. Regulatory Framework
8.4.1.5. Reimbursement Scenario
8.4.2. Mexico
8.4.2.1. Mexico Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.4.2.2. Market Dynamics
8.4.2.3. Competitive Landscape
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.3. Argentina
8.4.3.1. Argentina Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.4.3.2. Market Dynamics
8.4.3.3. Competitive Landscape
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.4. Colombia
8.4.4.1. Colombia Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.4.4.2. Market Dynamics
8.4.4.3. Competitive Landscape
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.5. Middle East and Africa
8.5.1. South Africa
8.5.1.1. South Africa Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.5.1.2. Market Dynamics
8.5.1.3. Competitive Landscape
8.5.1.4. Regulatory Framework
8.5.1.5. Reimbursement Scenario
8.5.2. Saudi Arabia
8.5.2.1. Saudi Arabia Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.5.2.2. Market Dynamics
8.5.2.3. Competitive Landscape
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.3. UAE
8.5.3.1. UAE Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.5.3.2. Market Dynamics
8.5.3.3. Competitive Landscape
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.4. Kuwait
8.5.4.1. Kuwait Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.5.4.2. Market Dynamics
8.5.4.3. Competitive Landscape
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.5. Rest of Middle East and Africa
8.5.5.1. Rest of MEA Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Mn)
8.5.5.2. Market Dynamics
8.5.5.3. Competitive Landscape
8.5.5.4. Regulatory Framework
8.5.5.5. Reimbursement Scenario
9. Competitive Landscape
9.1. Company Market Share Analysis, 2025
9.2. Company Tier Structure
9.3. List of Major Suppliers, By Key Countries
9.4. Key Company Positioning Analysis
9.5. Company Profile
9.5.1. Abbott Laboratories
9.5.2. AgaMatrix
9.5.3. ARKRAY Inc.
9.5.4. Ascensia Diabetes Care
9.5.5. B. Braun Melsungen AG
9.5.6. DarioHealth Corp.
9.5.7. Dexcom, Inc.
9.5.8. F. Hoffmann-La Roche Ltd
9.5.9. Insulet Corporation
9.5.10. Medisana AG
9.5.11. Medtronic plc
9.5.12. Senseonics Holdings, Inc.
9.5.13. Sinocare Inc.
9.5.14. Tandem Diabetes Care
9.5.15. Trividia Health
9.5.16. Ypsomed AG
10. Analyst Perspective
11. Related Reports
Related Research
Revolution Insights Briefs
Stay informed with updates on related market reports and key industry topics.